Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07399977
NA

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

Sponsor: Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.

Official title: A Nonrandomized Trial Using DNA Liquid Biopsies to Guide Anticoagulation For Patients With Cancer-Associated Thromboembolism

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

259

Start Date

2026-01-30

Completion Date

2030-01-30

Last Updated

2026-02-12

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

MSK-ACCESS

MSK-ACCESS is a ctDNA sequencing assay

DIAGNOSTIC_TEST

ctDNA/VTE Risk Score:

Machine learning Venous Thromboembolism/VTE risk score mode

Locations (8)

Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

Commack, New York, United States

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

New York, New York, United States

Memorial Sloan Kettering Nassau (All protocol activities)

Rockville Centre, New York, United States

Royal North Shore Hospital, Australia

Sydney, Australia